Consistent Outcomes across Dose Ranges with Titratable LixiLan, Insulin Glargine/Lixisenatide Fixed-Ratio Combination, in the LixiLan-O Trial

被引：0
|
作者：
Henry, Robert R.
Ahren, Bo
Davies, Melanie
Wu, Yujun
Handelsman, Yehuda
Souhami, Elisabeth
Niemoeller, Elisabeth
Rosenstock, Julio
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1017-P
引用
收藏
页码：A264 / A264
页数：1
相关论文
共 50 条
  • [31] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Frias, Juan P.
    Dex, Terry
    Roberts, Michelle
    Kaplan, Allen
    [J]. DIABETES THERAPY, 2019, 10 (01) : 21 - 33
  • [32] A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
    Juan P. Frias
    Terry Dex
    Michelle Roberts
    Allen Kaplan
    [J]. Diabetes Therapy, 2019, 10 : 21 - 33
  • [33] Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Frias, Juan P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1081 - 1089
  • [34] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    [J]. DIABETES, 2014, 63 : A87 - A88
  • [35] Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 : 3 - 13
  • [36] Shorter Time to Glycemic Control with Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Compared with Insulin Glargine Treatment Alone
    Frias, Juan P.
    Domingo, Manuel Puig
    Meneghini, Luigi F.
    Nap-Oli, Raffaele
    Liu, Minzhi
    Rak, Erika Soltes
    Aroda, Vanita R.
    [J]. DIABETES, 2017, 66 : A287 - A287
  • [37] Shorter time to glycaemic control with fixed-ratio combination of insulin glargine and lixisenatide compared with insulin glargine treatment alone
    Frias, J. P.
    Puig Domingo, M.
    Meneghini, L.
    Napoli, R.
    Liu, M.
    Soltes Rak, E.
    Aroda, V. R.
    [J]. DIABETOLOGIA, 2017, 60 : S369 - S370
  • [38] Impact of Dose Capping in Insulin Glargine/Lixisenatide Fixed-Ratio Combination Trials in Patients with T2D
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Meng, Zhaoling
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Wu, Yujun
    Mandema, Jaap
    Newton, John
    Meneghini, Luigi
    Frias, Juan
    [J]. DIABETES, 2017, 66 : A292 - A292
  • [39] Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial
    He, Yifan
    Yang, Wenying
    Dong Xiaolin
    Yuan, Guoyue
    Liu, Ming
    Xiao, Jianzhong
    Gu, Shenghong
    Chen, Lijuan
    Souhami, Elisabeth
    [J]. DIABETES, 2022, 71
  • [40] COST-EFFECTIVENESS OF INSULIN GLARGINE/LIXISENATIDE TITRATABLE FIXED-RATIO COMBINATION FOR PATIENTS WITH BASAL INSULIN-TREATED TYPE 2 DIABETES IN SOUTH KOREA
    Park, H.
    An, S.
    Park, S.
    Kim, D.
    Jeon, S.
    Kwon, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S38 - S38
12345